Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Feb 28;25(1):292.
doi: 10.1186/s12879-025-10562-w.

Prevalence of multidrug-resistant bacteria in healthcare and community settings in West Africa: systematic review and meta-analysis

Affiliations
Meta-Analysis

Prevalence of multidrug-resistant bacteria in healthcare and community settings in West Africa: systematic review and meta-analysis

Moustapha Diop et al. BMC Infect Dis. .

Abstract

Background: Multidrug-resistant (MDR) bacteria are a global health threat, notably in low- and middle-income countries. The aim of this review was to estimate the prevalence of multidrug-resistant bacteria in healthcare and community settings in West Africa.

Methods: In accordance with PRISMA guidelines, we searched PubMed, CINAHL, African Index Medicus, and other databases for studies published from 2010 onward. Data on MDR bacterial prevalence, study characteristics, and infection types were extracted and analyzed via R software. Subgroup analyses were performed to explore differences in prevalence across infection settings and sample types.

Results: Out of the 5,320 articles identified, 50 studies from 13 West African countries met the inclusion criteria, with the majority from Nigeria (34%) and Ghana (22%). Among the 35,820 bacteria isolated in these studies, gram-negative bacteria (GNB), particularly Escherichia coli and Klebsiella sp., were the most frequently isolated species, accounting for 63.3% of the bacteria. The overall prevalence of MDR bacteria was 59% (95% CI: 48-69%), with significant heterogeneity between studies (I² = 98%, p < 0.001). Subgroup analysis revealed a 7% increase in MDR bacteria prevalence from the first five-year period to the last two five-year periods, and a greater prevalence of MDR bacteria in nosocomial infections (65%, 95% CI: 45-81%) than in community-acquired infections (53%, 95% CI: 31-74%). The prevalence of MDR bacteria in mixed infection settings was 58% (95% CI: 44-71%). The MDR prevalence was highest in the urine samples (72%, 95% CI: 57-84%) and superficial skin samples (69%, 95% CI: 29-92%), whereas it was lowest in the nasopharyngeal samples (26%, 95% CI: 21-33%).

Conclusion: The high prevalence of MDR bacteria in West Africa underscores the need for strengthened infection control measures, improved surveillance, and stricter antibiotic use policies. Enhanced regional collaboration is essential to mitigate the spread of AMR in both healthcare and community settings.

Prospero registration number: CRD42023470363.

Keywords: MDR bacteria; Prevalence; West Africa.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
West African region
Fig. 2
Fig. 2
Flowchart of the studies selection
Fig. 3
Fig. 3
Number of studies included per country
Fig. 4
Fig. 4
Number of publications per year
Fig. 5
Fig. 5
Samples used in the studies
Fig. 6
Fig. 6
Top ten of isolated species
Fig. 7
Fig. 7
Global prevalence of MDR bacteria in West Africa
Fig. 8
Fig. 8
Risk of publication bias assessment
Fig. 9
Fig. 9
Prevalence of MDR bacteria per 5-year period of publication
Fig. 10
Fig. 10
Prevalence of MDR bacteria per infection type
Fig. 11
Fig. 11
Prevalence of MDR bacteria per sample type

Similar articles

Cited by

References

    1. OMS. Plan d’action mondial pour combattre la résistance aux antimicrobiens [Internet]. Genève: Organization mondiale de la Santé; 2016 [cited 2024 Oct 24]. 21 p. Available from: https://iris.who.int/handle/10665/249548
    1. O’NEILL J. Review on antimicrobial resistance: tackling drug-resistant infections globally: final report and recommendations. 2016 [Internet]. [cited 2024 Oct 24]. Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20c...
    1. Berthuim J, Miras M. La résistance aux antibiotiques: un enjeu de santé publique et économique. Bpi Fr Serv L’avenir; 2018.
    1. Global antimicrobial resistance and use surveillance. System (GLASS) report 2022. Geneva: World Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO.
    1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 20221;399(10325):629–55. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources